30 closest matches · ranked by relevance
Mycoses · Sezary Syndrome · Lymphoma, T-Cell, Cutaneous
Primary: Progression-Free Survival (PFS) at 180 Days — 73 percentage of participants
Lymphoma
Primary: Overall Response Rate After 2 Courses of Treatment
Lymphoma · Disorder Related to Bone Marrow Transplantation
Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants
Cutaneous T-Cell Lymphoma
Primary: Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion…
Lymphoma · T-Cell · Cutaneous
Primary: Response Rate — 0; 0; 1; 1 Participants
Cutaneous T Cell Lymphoma
Primary: The Number of Participants That Tolerated the Maximum Drug Dose — 8; 4 Participants
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Cutaneous T-Cell Lymphoma
Primary: Overall Response Rate of Participants Using the Modified Severity-Weighted Assessment Tool (mSWAT) — 16.7; 20.3; 18.5 percentage
Lymphoma
Primary: Median Progression-free Survival — 5 months
Cutaneous T Cell Lymphoma
Primary: Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity…
Persistent or Recurrent Cutaneous T-Cell Lymphoma
Primary: Lead-In Part: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03…
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma · Recurrent Mycosis Fungoides/Sezary Syndrome · Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Primary: MTD of Photodynamic Therapy — 150 J/cm^2
Lymphoma
Primary: Parts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE) — 10; 6 participants
Lymphoma, T-Cell, Cutaneous
Primary: Percentage of Patients With Complete or Partial Response as Measured by Change in Lesion Severity Using CAILS (Composite Assessment of Index Lesion Severity) — 27; 0…
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Cutaneous T-cell Lymphoma
Primary: The Percent of Patients (Pts) With Objective Disease Response — 34 Percent of participants
Cutaneous T-Cell Lymphoma
Primary: Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Among Mycosis Fungoides (MF) and Sezary Syndrome (SS) Participants (Response…
Mycosis Fungoides · Sezary Syndrome
Primary: Efficacy of Nonmyeloablative Preparative Regimen — 4 Participants
T Cell Lymphoma
Primary: Overall Response Rate — 5 participants
Refractory Cutaneous T-cell Lymphoma
Primary: Number of Participants With Tumor Response (Complete Response [CR], Clinical Complete Response [CCR], and Partial Response [PR]) in up to 5 Index Lesions as Determined…
Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) and Recommended Dose (RD) — 9 ug/kg/day
Primary Cutaneous Anaplastic Large Cell Lymphoma · Mycosis Fungoides · Cutaneous T-Cell Lymphoma
Primary: Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4) — 54.7; 12.5 percentage of participants — p=<0.001
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Global Composite Response (Skin, Blood, Lymph Nodes)as Determined by Skin Evaluations, Blood Counts and PET/CT Imaging — 260; 260; 232 days
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Objective Response Rate (ORR) — 41.2; 31.6 percentage of participants
Non-Hodgkin Lymphoma (NHL) · Cutaneous Lymphoma · Cutaneous T-cell Lymphoma (CTCL)
Primary: Overall Response Rate (ORR) — 70; 56; 79; 100 percentage
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7 · Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7
Primary: Overall Response Rate — 6; 2; 8; 1 participants
Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose — 0; 0; 0; 0 Participants
Lymphoma
Primary: Response to Treatment — 0; 9 participants
Lymphoma
Primary: Objective Response Rate — .25 proportion of participants
Lymphoma
Primary: Dose Limiting Toxicity (DLT) — 0; 1; 1 Participants